An observational study in Multiple Myeloma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 130 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's planned enrollment of 2,555 is above the median of 140 across 468 observational studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population will consist of two cohorts: Participants with relapsed/refractory (RR) multiple myeloma (MM) and those with newly-diagnosed (ND) multiple myeloma (MM).
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
For RRMM participants who have received at least one prior line of therapy (LoT) for MM:
For NDMM participants receiving frontline therapy:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Participants with relapsed/refractory multiple myeloma (RRMM) followed up for up to 5 years
Participants with newly-diagnosed multiple myeloma (NDMM) followed up for up to 8 years
Overall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM)
Time frame: Up to 5 years
Overall Survival (OS) for participants with newly-diagnosed multiple myeloma (NDMM)
Time frame: Up to 8 years
Progression-Free Survival (PFS) for participants with RRMM
Time frame: Up to 5 years
Progression-Free Survival (PFS) for participants with NDMM
Time frame: Up to 8 years
Treatment patterns of approved MM therapies as measured by the Response Rate for participants with RRMM
Time frame: From study index date until the enrollment date, assessed up to 5 years
Treatment patterns of approved MM therapies as measured by the Response Rate for participants with NDMM
Time frame: From study index date until the enrollment date, assessed up to 8 years
Healthcare resource utilization (HCRU) for participants with RRMM
Time frame: Up to 5 years
Healthcare resource utilization (HCRU) for participants with NDMM
Time frame: Up to 8 years
Healthcare resource utilization (HCRU) for participants with RRMM
Time frame: From the day of enrollment until death, withdrawal of consent, enrollment into a clinical trial for MM, loss to follow-up, or end of study, whichever comes first; assessed up to 60 months
Healthcare resource utilization (HCRU) for participants with NDMM
Time frame: From the day of enrollment until death, withdrawal of consent, enrollment into a clinical trial for MM, loss to follow-up, or end of study, whichever comes first; assessed up to 96 months
Patient reported outcomes as measured by EQ-5D summary index for participants with RRMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 5 years
Patient reported outcomes as measured by EQ-5D summary index for participants with NDMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 8 years
Patient reported outcomes as measured by EORTC-QLQ-C30 for participants with RRMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 5 years
Patient reported outcomes as measured by EORTC-QLQ-C30 for participants with NDMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 8 years
Patient reported outcomes as measured by EORTC-QLQ-MY20 for participants with RRMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 5 years
Patient reported outcomes as measured by EORTC-QLQ-MY20 for participants with NDMM
Time frame: From start of initial therapy to questionnaire completion, assessed up to 8 years
Incidence of Adverse Events (AEs) for participants with RRMM
Time frame: Up to 5 years
Incidence of Adverse Events (AEs) for participants with NDMM
Time frame: Up to 8 years
Showing the first 100 of 130 sites across 6 countries.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb